After stopping antiplatelet therapy while continuing apixaban (5 mg twice daily) for pulmonary embolism in a trauma patient, how long should lansoprazole 15 mg daily be continued before it can be stopped?

Lansoprazole Should Be Stopped Immediately After Antiplatelet Cessation

Lansoprazole 15 mg daily should be discontinued as soon as antiplatelet therapy is stopped, as there is no indication to continue proton pump inhibitor (PPI) therapy solely for apixaban monotherapy in a trauma patient with PE.

Rationale for Immediate Discontinuation

The primary indication for lansoprazole in this context was gastrointestinal (GI) protection during dual antithrombotic therapy (antiplatelet + anticoagulant). Once antiplatelets are discontinued and the patient remains on apixaban monotherapy alone, the bleeding risk profile changes substantially:

• Apixaban monotherapy does not routinely require PPI prophylaxis unless there are specific GI risk factors (active ulcer disease, prior GI bleeding, concurrent NSAIDs, or high-dose corticosteroids)
• PPIs are not recommended as routine prophylaxis for patients on anticoagulation alone 1
• The trauma-related indication has resolved with antiplatelet cessation

Clinical Context: Trauma-Related PE

In this trauma patient with PE:

• Trauma represents a major transient risk factor for VTE 2, 3, 2
• After 3 months of anticoagulation for trauma-provoked PE, guidelines recommend against extended-phase anticoagulation (strong recommendation) 3, 2, 3
• The patient should be reassessed at 3 months to determine if apixaban itself can be discontinued 2

PPI Deprescribing Considerations

Stopping lansoprazole abruptly is appropriate in this clinical scenario:

• At the low dose of 15 mg daily, rebound acid hypersecretion is less pronounced than with higher doses
• If rebound symptoms occur (typically lasting 2-4 weeks), they can be managed with:
  • On-demand antacids (calcium carbonate, magnesium hydroxide)
  • H2-receptor antagonists as needed
  • Patient education about temporary nature of symptoms 4

Important Caveats

Continue lansoprazole only if:

• History of peptic ulcer disease or prior GI bleeding
• Concurrent NSAID use (should be avoided if possible on anticoagulation)
• Active dyspepsia or GERD symptoms unrelated to antiplatelet therapy
• High-dose corticosteroid therapy

Do NOT continue lansoprazole:

• "Just in case" or for indefinite prophylaxis on apixaban alone
• Without documented GI indication beyond the discontinued antiplatelet therapy
• Long-term PPI use carries risks (C. difficile infection, fractures, nutrient malabsorption) that outweigh benefits in low-risk patients 4

Practical Management Algorithm

1. Day of antiplatelet cessation: Stop lansoprazole
2. Counsel patient about possible mild dyspepsia for 2-4 weeks (rebound effect)
3. Provide antacids for symptomatic relief as needed
4. Reassess at 3 months: Evaluate whether apixaban can be discontinued given trauma-provoked PE 3, 2
5. If apixaban continues beyond 3 months: Consider dose reduction to apixaban 2.5 mg twice daily for extended therapy if indicated 2

The evidence clearly supports that PPI prophylaxis is indicated for dual antithrombotic therapy (antiplatelet + anticoagulant) or triple therapy (dual antiplatelet + anticoagulant), but not for anticoagulant monotherapy in the absence of specific GI risk factors 1, 5.